EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Study on the Efficacy and Pharmacological Mechanism of Liposome Complexes Containing STING Agonist and Anti-PD-L1 Nanobody in Inhibiting HCC

Xiaoqing Wang iD, Xing Lu, Chang Liu, Hao Cheng, Xiangshi Tan

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26178649 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Xiaoqing Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Fudan University, Shanghai 200433, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liposomes, Liver Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Science Foundation of China, National Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The low immunogenicity and immune escape are bottlenecks for effective hepatocellular carcinoma (HCC) immunotherapy. We prepared and characterized a dual-target liposome complex, XA5508, by encapsulating the STING agonist cGAMP in liposomes and conjugating an anti-PD-L1 nanobody to the liposome surface. The anti-tumor effect and pharmacological mechanism of XA5508 were investigated using an in situ HCC mouse model. XA5508 can effectively inhibit in situ HCC with the characteristics of tumor-targeted delivery and sustained release of STING agonist cGAMP. The pharmacological mechanism study indicates that XA5508 activates the STING signaling pathway, increases the cytotoxicity of CD8+ T cells, reverses the immunosuppressive tumor microenvironment (TME) represented by M2-type macrophages, and transforms cold tumors into hot tumors. On the other hand, cGAMP induces the upregulation of PD-L1 expression in HCC, enhances the response of anti-PD-L1 nanobody (Nb) and the escape blockade of immune checkpoint PD-1/PD-L1. XA5508 shows remarkable anti-tumor effects of STING agonist and anti-PD-L1 nanobody against HCC, providing an innovative strategy for the development of new drugs for HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiposomesLiver NeoplasmsB7-H1 AntigenSingle-Domain AntibodiesMembrane ProteinsAnimalsMiceHumansTumor MicroenvironmentCell Line, TumorImmunotherapyNucleotides, CyclicCD8-Positive T-LymphocytesSTING Protein

Stichwörter der Autor:innen

STING agonistanti-PD-L1 nanobodycGAMPhepatocellular carcinoma (HCC)nanobody

Substanzen

LiposomesB7-H1 AntigenSingle-Domain AntibodiesMembrane ProteinsNucleotides, CyclicSting1 protein, mouseSTING ProteinCD274 protein, humancyclic guanosine monophosphate-adenosine monophosphate

Autor:innen und Institutionen

  • Department of Chemistry, Fudan University, Shanghai 200433, China.

ORCID-Profile: Xiaoqing Wang

Förderung

  • the National Science Foundation of China
  • National Science Foundation of China

Zitieren

APA

Wang, X., Lu, X., Liu, C., Cheng, H., & Tan, X. (2025). A Study on the Efficacy and Pharmacological Mechanism of Liposome Complexes Containing STING Agonist and Anti-PD-L1 Nanobody in Inhibiting HCC. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178649

Vancouver

Wang X, Lu X, Liu C, Cheng H, Tan X. A Study on the Efficacy and Pharmacological Mechanism of Liposome Complexes Containing STING Agonist and Anti-PD-L1 Nanobody in Inhibiting HCC. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178649

BibTeX
@article{Wang2025,
  author = {Wang, Xiaoqing and Lu, Xing and Liu, Chang and Cheng, Hao and Tan, Xiangshi},
  title = {A Study on the Efficacy and Pharmacological Mechanism of Liposome Complexes Containing STING Agonist and Anti-PD-L1 Nanobody in Inhibiting HCC},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26178649}
}
Kostenlos starten →